Phase 2 Peripheral Neuropathy Trial, Recruiting NCT05732831 Sponsor: Tango Therapeutics, Inc. Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Phase 2 Peripheral Neuropathy Trial, Recruiting

NCT05732831
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older at the time of signing the consent form
  • You are reasonably active and able to care for yourself, with only mild limitations on physical activity (confirm with trial site)
  • You have been diagnosed with a solid tumor that has spread, cannot be surgically removed, or is locally advanced, confirmed by a tissue or cell sample
  • You have already received standard treatments that were available to you
  • Your tumor has been tested and shown to have a specific genetic change — a missing gene called MTAP — detected by genetic testing or a lab protein test
  • Your liver, kidneys, and other organs are functioning well enough based on recent blood tests
  • If you are able to become pregnant, you have a negative pregnancy test at the start of the study
  • You are willing and able to sign a written consent form

Who may not be able to join:

  • You have a known allergy or serious reaction to the study drugs (TNG462 or pembrolizumab) or their ingredients
  • You have another serious illness that is not well controlled and could affect your ability to take part in the study
  • You currently have an active infection that requires treatment with medication given into the bloodstream
  • You are currently taking part in, or planning to join, another clinical trial testing a different experimental drug or device
  • You have a stomach or bowel condition that could affect how your body absorbs the oral study drug
  • You have another active cancer at the same time (confirm with trial site)
  • You have cancer that has spread to the brain and is causing worsening symptoms
  • You currently have an active liver disease of any kind
  • You are HIV positive, unless your immune cell count, viral levels, and HIV treatment all meet specific requirements (confirm with trial site)
  • You have a significant heart or blood vessel condition (confirm with trial site)
  • You are pregnant or currently breastfeeding
  • You are unwilling or unable to attend scheduled visits, take the study drug as planned, or follow other study requirements
  • In the doctor's opinion, you have another medical condition or history that could affect your safety or the reliability of the study results

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Maxim Pimpkin, MD, Tango Therapeutics, Inc.

Phone: (857) 320-4899

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Tango Therapeutics, Inc.
Registry
ClinicalTrials.gov
Start date
26 May 2023
Est. completion
1 May 2026

Where this trial is recruiting

🇫🇷 France 🇪🇸 Spain 🇺🇸 United States

Primary endpoints

Phase 1 Maximum Tolerated Dose; Phase 1 Dosing Schedule; Phase 2 Anti-neoplastic Activity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov